Parabolan~Trenbolone Hexahydrobenzylcarbonate

[TwisT]

Parabolan

Parabolan is simply Trenbolone, but with the hexahydrobenzylcarbonate ester chain to make it active in the body for over two weeks. Parabolan will effect you just as any trenbolone will, while having a much longer active life in the body. Side effects may differ slightly then a short ester version. Please see http://www.ironmagazineforums.com/a...-finaplex-trenbolone-acetate.html#post2132550.

Androgenic: 500
Anabolic: 500
Standard: Nandrolone Acitate
Chemical Name: 17beta-Hydroxyestra-4,9,ll-trien-3-one
Estrogenic Activity: none
Progestational Activity: moderate

Description:
Trenbolone hexahydrobenzylcarbonate is a slow-acting injectable ester of the potent anabolic steroid trenbolone. Trenbolone appears most commonly as trenbolone acetate, which is a much faster-acting form of the drug (see: Finajet). The hexahydrobenzylcarbonate ester used here extends the release of trenbolone for more than 2 weeks, which has always been thought of as more suitable for human use due to the less frequent injection schedule. The base steroid trenbolone is roughly three times more androgenic than testosterone, making it a fairly potent androgen. It also displays about 3 times greater tissue- building activity in comparison to its androgenic properties, making its official classification as that of an anabolic steroid. The muscle-building effect of trenbolone is often compared to such popular bulking agents as testosterone or Dianabol, but without the same estrogen- related side effects. It is most commonly identified as a lean-mass-building drug, and is extremely popular with athletes for its ability to promote the rapid buildup of strength, muscle size, and definition.

Reference:
Llewellyn???s W. (2009). Anabolics (9th ed), Parabolan (p. 353): Jupiter, FL: Molecular Nutrition

 

[heavyiron]

Am J Physiol Endocrinol Metab. 2011 Jan 25. [Epub ahead of print]

17{beta}-hydroxyestra-4,9,11-trien-3-one (Trenbolone) Exhibits Tissue Selective Anabolic Activity: Effects on Muscle, Bone, Adiposity, Hemoglobin, and Prostate.

Yarrow JF, Conover CF, McCoy SC, Lipinska JA, Santillana CA, Hance JM, Cannady DF, Vanpelt TD, Sanchez J, Conrad BP, Pingel JE, Wronski TJ, Borst SE.
1VA Medical Center.

Abstract

Selective androgen receptor modulators (SARMs) now under development can protect against muscle and bone loss, without causing prostate growth or polycythemia. 17β-hydroxyestra-4,9,11-trien-3-one (trenbolone), a potent testosterone analogue, may have SARM-like actions because, unlike testosterone, trenbolone does not undergo tissue-specific 5α reduction to form more potent androgens. We tested the hypothesis that trenbolone-enanthate (TREN) might prevent orchiectomy-induced losses in muscle and bone and visceral fat accumulation, without increasing prostate mass or resulting in adverse hemoglobin elevations. Male F344 rats aged three months underwent orchiectomy or remained intact and were administered graded doses of TREN, supraphysiologic testosterone-enanthate, or vehicle for 29 days. In both intact and orchiectomized animals, all TREN doses and supraphysiologic testosterone-enanthate augmented androgen-sensitive levator ani/bulbocavernosus muscle mass by 35-40% above Shams (p≤0.001), and produced a dose-dependent partial protection against orchiectomy-induced total and trabecular bone mineral density losses (p<0.05) and visceral fat accumulation (p<0.05). The lowest doses of TREN successfully maintained prostate mass and hemoglobin concentrations at Sham levels in both intact and orchiectomized animals; whereas supraphysiologic testosterone-enanthate and high-dose TREN elevated prostate mass by 84% and 68%, respectively (p<0.01). In summary, low dose administration of the non-5α reducible androgen TREN maintains prostate mass and hemoglobin concentrations near the level of Shams, while producing potent myotrophic actions in skeletal muscle and partial protection against orchiectomy-induced bone loss and visceral fat accumulation. Our findings indicate that TREN has advantages over supraphysiologic testosterone and supports the need for future pre-clinical studies examining the viability of TREN as an option for androgen replacement therapy.


PMID: 21266670 [PubMed - as supplied by publisher]